Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)
肿瘤科
胰腺神经内分泌肿瘤
神经内分泌肿瘤
作者
James C. Yao,J. Strosberg,Nicola Fazio,Marianne Pavel,Philippe Ruszniewski,Emily K. Bergsland,Daneng Li,Salvatore Tafuto,Nitya Raj,Davide Campana,Susumu Hijioka,Markus Raderer,Rosine Guimbaud,Pablo Gajate,Sara Pusceddu,Albert Reising,Evgeny Degtyarev,Bijoyesh Mookerjee,Paola Aimone,Simron Singh